Navigation Links
Puma Biotechnology Announces Positive PB272 (Neratinib) Phase II Data at CTRC-AACR San Antonio Breast Cancer Symposium
Date:12/9/2011

a median of 3 prior cytotoxic regimens (range 1-12 prior regimens).  Patients in the HER2+ cohort of the trial received a median of 2 prior trastuzumab containing regimens (range 1-9 prior regimens).  Patients were administered PB272 at a dose of 240 mg per day in combination with temsirolimus given at a dose of 8 mg weekly.

The results of the study presented showed that the combination of PB272 and temsirolimus had acceptable tolerability.  The most frequently observed severe adverse events for the 20 patients evaluable for safety were grade 3 diarrhea (10% of patients), grade 3 hyperglycemia (5%), mucositis (5%), leukopenia (5%), and fatigue (5%). The efficacy results from the trial showed that for the 15 patients with HER2+ disease, 9 (60%) patients experienced a partial response and 1 (7%) patient experienced stable disease for greater than 6 months, which translates to a clinical benefit rate of 67%.  Patients who experienced a partial response to the combination of neratinib plus temsirolimus demonstrated a maximum change in the size of their target lesions of between 33% and 83%.  None of the 5 patients with triple negative breast cancer demonstrated a partial response or stable disease for greater than 6 months.

Alan H. Auerbach, Chief Executive Officer and President of Puma Biotechnology, said, "We are pleased with the PB272 data that has been presented at the San Antonio Breast Cancer Symposium.  The combination of PB272 given in combination with capecitabine shows strong evidence of antitumor activity in second and third line HER2+ metastatic patients, which we believe could position the drug well compared to other agents currently used to treat second and third line disease.  In addition, the data on the combination of PB272 in combination with temsirolimus demonstrates intriguing antitumor activity in a heavily pretreated population.  We look forward to continuing to study both of these combination
'/>"/>

SOURCE Puma Biotechnology, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. The European Union Signs Grant Contract to Fund a 2 Million Euro Biotechnology Research Project Led by Hadassah College Jerusalem
2. Animal Biotechnology - Technologies, Markets and Companies
3. Puma Biotechnology Announces Completion of Private Placement
4. HUYA Bioscience International Builds Long-Term Relationship with Shenzhen Polytechnic School of Applied Chemistry and Biotechnology
5. Congressman Eric Cantor and Health Diagnostic Laboratory, Inc. Discuss Job Growth at Virginia BioTechnology Research Park
6. Industrial Biotechnology China News 1109 - Annual Subscription
7. Nanobiotechnology: Applications and Global Markets
8. Californias Industrial Biotechnology Workforce: Creating Jobs and Leading Innovation
9. Global Biotechnology Instrumentation Industry
10. Separation Systems for Commercial Biotechnology
11. TWi Biotechnology Successfully Completes Patient Recruitment for Phase IIb Trial of AC-201 for the Treatment of Type II Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... , July 30, 2014  Orexigen Therapeutics, Inc. (Nasdaq: ... the Day 180 List of Outstanding Issues (LOI) from ... Human Use (CHMP) for the NB32 Marketing Authorization Application ... is an investigational drug candidate being evaluated for weight ... Day 120 time point were adequately addressed by the ...
(Date:7/30/2014)...  AtheroNova Inc. (OTCBB: AHRO), a biotech company ... to safely regress atherosclerotic plaque and improve lipid ... CardioNova, has accomplished first dosing of subjects for ... compound, AHRO-001.  This Phase 1b trial will be ... trial completed in February 2014, in which patients ...
(Date:7/30/2014)... July 30, 2014 Vala Sciences ... U.S. Environmental Protection Agency (EPA). This new contract ... toxicity models, including tests designed to assess the ... the formation of connections between neurons (synapses), which ... and synapse formation by environmental pollutants likely contributes ...
(Date:7/29/2014)... July 30, 2014 SoundConnect ... collaboration company, is proud to announce the strategic ... positions in their Boston, Charleston and Atlanta offices. ... the increased demand for hosted solutions, collaboration and ... and reduce cost. , SoundConnect was founded in ...
Breaking Biology Technology:Orexigen Receives CHMP Day 180 List of Outstanding Issues 2Orexigen Receives CHMP Day 180 List of Outstanding Issues 3AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 2AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 3AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 4U.S. Environmental Protection Agency (EPA) Awards Vala Sciences a Second ToxCast Contract 2U.S. Environmental Protection Agency (EPA) Awards Vala Sciences a Second ToxCast Contract 3SoundConnect Organization and Culture is Evolving 2
... July 14 Bio-Optronics, Inc., a leader in healthcare workflow ... software solution that can simultaneously handle the most intricate scheduling ... staff schedules. , , Physician ... , Bio-Optronics President & CEO, ...
... , HALIFAX, NS, July 14 /PRNewswire/ - ImmunoVaccine ... entered into an agreement to exclusively license seven ... company. These proprietary antigens specifically target breast, ovarian ... antigens with its DepoVax(TM) delivery platform to develop ...
... , , TAMPA, Fla., July ... on the research and development of cancer immunotherapies, announces that the ... its dendritic cell therapy. , , ... I/II clinical trial testing the safety and efficacy of its immunotherapy ...
Cached Biology Technology:NEW Momentum(TM) Physician and Staff Scheduling Software for Imaging Centers, OB/GYN, and Other Specialty Practices Improves Productivity and Equity in Scheduling 2ImmunoVaccine Technologies Licenses Immunotope's Breast, Ovarian and Prostate Cancer Antigens 2Significant Milestone Marks the Beginning of FDA-Authorized Breast Cancer Trial 2Significant Milestone Marks the Beginning of FDA-Authorized Breast Cancer Trial 3
(Date:7/30/2014)... biologists, led by Clemson University associate professor Andrew S. ... will pave the way for novel anti-fouling paint for ... and industrial applications. , The team,s findings, published in ... larval stage of barnacles that attaches to a wide ... material that acts as an underwater heavy-duty adhesive. , ...
(Date:7/30/2014)... Portland Press Limited today announced an across-the-board increase ... , The 2013 InCites Journal Citation Reports (Thomson ... Biochemical Journal , Essays in Biochemistry ... Bioscience Reports all received increases in their ... Biochemical Society and published by Portland Press Limited. ...
(Date:7/30/2014)... A professor from Wayne State University,s College of ... National Science Foundation for the project, "Nanoparticle-directed synthesis ... National Science Foundation, nanotechnology is the creation and ... novel properties and functions. A major bottleneck in ... methods that connect different functional materials into one ...
Breaking Biology News(10 mins):Study: Marine pest provides advances in maritime anti-fouling and biomedicine 2Across-the-board Impact Factor increases for Portland Press Limited 2NSF grant to Wayne State supports new concept for manufacturing nanoscale devices 2
... have created the first three-dimensional living tissue model, complete ... therapeutics to combat brain tumors. The 3-D model gives ... tissue cultures. The researchers created a glioma, or ... surrounds it. In a series of experiments, the team ...
... have succeeded in changing the genetic material of cancer ... in nanosurgery opens the door to new medical applications, ... A light scalpel to treat cancerous cells, The ... team uses a femtosecond laser (a laser with ultra-short ...
... Resolving the world,s major challenges whether climate change, ... scarcity requires a sweeping shift in our approach ... leading scientists told European policy makers today during ... and Societal Challenges for our Unstable Earth" (RESCUE). ...
Cached Biology News:Researchers make living model of brain tumor 2Europe needs a 'RESCUE' revolution 2Europe needs a 'RESCUE' revolution 3